Login / Signup

Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial.

Corinne E GriguerClaudia R OlivaChristopher S CoffeyMerit E CudkowiczRobin A ConwitAnna L GudjonsdottirDixie J EcklundJanel K FedlerTina M Neill-HudsonLouis B NaborsMelanie BengeJames R HackneyMarianne ChaseTimothy P LeonardToral PatelHoward ColmanMacarena de la FuenteRekha ChaudharyKaren MarderTeri KreislNimish MohileMilan G ChhedaKatharine McNeillPriya U KumthekarAclan DoganJan DrappatzVinay PuduvalliAgnes KowalskaJerome GraberElizabeth GerstnerStephen ClarkMichael SalaczJames M Markert
Published in: Neuro-oncology advances (2021)
promoter may reveal a subgroup of GBM patients with improved long-term survival that warrants further evaluation. Our work also demonstrates the importance of performing large, multi-institutional, prospective studies to validate biomarkers. We also discuss lessons learned in assembling such studies.
Keyphrases
  • newly diagnosed
  • clinical trial
  • case control
  • dna methylation
  • transcription factor
  • genome wide
  • study protocol
  • randomized controlled trial
  • phase ii
  • open label
  • clinical evaluation